Studies have shown that cetuximab not only activates p38 MAPK to inhibit the Nrf2/HO-1 axis to enhance RSL3-induced ferroptosis, but also enhances the cytotoxic effect of RSL3 on KRAS-mutant CRC cells, which may be promising to help develop attractive therapeutic strategies for patients with KRAS-mutant CRC (81). The gene discussed is KRAS; the disease is colorectal carcinoma.